|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's range||34.40 - 36.10|
|52-week range||20.60 - 54.68|
|Beta (5Y monthly)||2.19|
|PE ratio (TTM)||17.66|
|Earnings date||14 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||50.40|
Individual investors who want help picking stocks have more than a few options to choose from, including the recommendations of Wall Street analysts. Right now, InMode (NASDAQ: INMD) is a medical technology stock that analysts on Wall Street can't seem to get enough of. Among those who follow InMode, the average analyst is targeting a 47% gain for the stock over the next year.
It's important to remember, though, that today's economic troubles and stock market downturn are temporary. Certain growth stocks may suffer in this sort of context. One is a medical technology company that's set to report record earnings.
These stocks are all down by at least 42% from their all-time highs despite impressive performances from their underlying businesses.